Boehringer Ingelheim Partners With Ribo in $2B Deal to Develop Liver Therapies

Suzhou Ribo Life Science and Ribocure Pharmaceuticals (Ribo) announced a $2 billion collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). Source: Drug Industry…

Continue ReadingBoehringer Ingelheim Partners With Ribo in $2B Deal to Develop Liver Therapies

Nature Study Says Weight-Loss Blockbusters Don’t Correlate With Suicidal Ideation Just Days After FDA Indicates Its Concern Over the Risk

While the FDA has signaled concerns that drugs like Ozempic and Wegovy (semaglutide) come with an increased risk of suicidal ideation, a new study in the journal Nature says they…

Continue ReadingNature Study Says Weight-Loss Blockbusters Don’t Correlate With Suicidal Ideation Just Days After FDA Indicates Its Concern Over the Risk